Reading time: 5 minutes Share this article: The cell therapy industry stands on the edge of a transformative era. With advancements in treatment options and scalable manufacturing processes, companies like DiscGenics™ are leading the charge, delivering innovative therapies for previously intractable conditions. Simultaneously, market dynamics are shifting, with renewed investor confidence signaling …
Key Points Exbumin®, recombinant human serum albumin (rHSA), demonstrated superior T cell viability, health, and proliferation post-cryopreservation compared to clinical HSA and a 10% DMSO solution. Notably, this was achieved with only 2.5% DMSO, demonstrating Exbumin’s ability to reduce DMSO concentrations without compromising cell health. Exbumin is an approved excipient for therapeutic injection and offers …
Key Points Optibumin®, InVitria’s high-purity recombinant human albumin, performs comparably to serum-derived albumin in cell wash experiments, retaining nearly all cells and maintaining excellent viability after washing. Optibumin offers the additional benefits of animal-free origin and consistent quality. Introduction Downstream cell washing is a critical step in cell therapy manufacturing processes (Figure 1). During this …
